M1412 Met nsclc with egfr alk oth ab
M-Codes
Also known as: EGFR/ALK positive NSCLC, molecular mutation NSCLC, met nsclc w/ egfr alk
Performance measure documenting metastatic non-small cell lung cancer with sensitizing EGFR or ALK mutations or other actionable aberrations. Captures molecularly-driven treatment eligibility.
Clinical Context
Documents presence of sensitizing EGFR, ALK, ROS1, or NTRK mutations in metastatic non-small cell lung cancer, indicating targeted therapy eligibility.
RVU Breakdown
| Work RVU | 0.00 |
| Practice Expense RVU | 0.00 |
| Malpractice RVU | 0.00 |
| Total RVU | 0.00 |
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.